Stada Arzneimittel AG - Company Profile
Powered by 
All the data and insights you need on Stada Arzneimittel AG in one report.
$295
- Save hours of research time and resources with
our up-to-date Stada Arzneimittel AG Strategy Report
- Understand Stada Arzneimittel AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Stada Arzneimittel AG (STADA), a subsidiary of Nidda Healthcare GmbH, is a manufacturer of low-cost generics and branded over-the-counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. The company offers portfolio of products in various therapeutic categories including pain, women's health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin and Epoetin zeta. Its major branded products include APO-Go, Grippostad, Snup and Fultium. The company operates across Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.
Headquarters
Germany
Address
Stadastrasse 2-18, Bad Vilbel, Hessen, 61118
Website
www.stada.com
Telephone
49 6101 6030
No of Employees
13,183
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$4.0B
Stada Arzneimittel AG premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic: | Zoflora |
| Unbranded and Branded Generics | Snup |
| Speciality Pharmaceuticals | Nizoral |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In July, the company signed an agreement to acquire Sanofi consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain and the UK, as well as Nordic countries. |
| 2023 | Regulatory Approval | In June, the company received approval from U.S. FDA for biologics facility to supply key medicines to patients in the US. |
| 2023 | Contracts/Agreements | In May, the company entered into agreements with Alvotech SA to terminate the license and supply agreements between Alvotech and STADA pertaining to Alvotech's product candidates AVT03, AVT05 and AVT16. |
Competitor Comparison
| Key Parameters | Stada Arzneimittel AG | Evotec SE | Biotest AG | MPA Pharma GmbH | MorphoSys AG |
|---|---|---|---|---|---|
| Headquarters | Germany | Germany | Germany | Germany | Germany |
| City | Bad Vilbel | Hamburg | Dreieich | Trittau | Planegg |
| State/Province | Hessen | Baden-Wurttemberg | Hessen | Schleswig-Holstein | Bayern |
| No. of Employees | 13,183 | 5,086 | 2,426 | 470 | 524 |
| Entity Type | Private | Public | Public | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Günter von Au | Chairman | Executive Board | 2017 | 72 |
| Peter Goldschmidt | Chief Executive Officer | Senior Management | 2018 | - |
| Miguel Pagan Fernandez | Chief Technical Officer | Senior Management | 2018 | - |
| Simone Berger | Chief Human Resources Officer | Senior Management | 2021 | - |
| Markus Damm | Deputy Chairman | Executive Board | 2019 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward